Literature DB >> 19013497

DHEA metabolism in prostate: For better or worse?

Julia T Arnold1.   

Abstract

Dehydroepiandrosterone (DHEA) is commonly used in the USA as a nutritional supplement for antiaging, metabolic support or other uses. Investigations into understanding the effects of DHEA on human prostate cancer progression have posed more questions than answers and highlight the importance of communications between stromal and epithelial tuoitiuot elements within the prostate that contribute to the regulation of DHEA metabolism. Intracrine metabolism of DHEA to androgens (A) and/or estrogens (E) may occur in one cell compartment (stromal) which may release paracrine hormones or growth/inhibitory factors to the epithelial cells. Alternatively no metabolism of DHEA may occur, resulting in no harmful consequences of high levels of DHEA in prostate tissues. We herein review the tissue components involved and interactions with the prohormone, DHEA and/or resulting metabolites, including dihydrotestosterone (DHT) or 17beta-estradiol (E(2)) in an in vitro model of endocrine-immune-paracrine interactions within the prostate. This work raises questions and hypotheses concerning the role of DHEA in prostate in normal tissues, vs. preneoplastic tissues.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19013497      PMCID: PMC2667103          DOI: 10.1016/j.mce.2008.10.019

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  65 in total

1.  Chemoprevention of rat prostate carcinogenesis by early and delayed administration of dehydroepiandrosterone.

Authors:  K V Rao; W D Johnson; M C Bosland; R A Lubet; V E Steele; G J Kelloff; D L McCormick
Journal:  Cancer Res       Date:  1999-07-01       Impact factor: 12.701

2.  Induction of 3beta-hydroxysteroid dehydrogenase/isomerase type 1 expression by interleukin-4 in human normal prostate epithelial cells, immortalized keratinocytes, colon, and cervix cancer cell lines.

Authors:  S Gingras; J Simard
Journal:  Endocrinology       Date:  1999-10       Impact factor: 4.736

Review 3.  Estrogen receptor-beta: implications for the prostate gland.

Authors:  W Y Chang; G S Prins
Journal:  Prostate       Date:  1999-07-01       Impact factor: 4.104

Review 4.  Is there a receptor for dehydroepiandrosterone or dehydroepiandrosterone sulfate?

Authors:  Richard L Widstrom; Joseph S Dillon
Journal:  Semin Reprod Med       Date:  2004-11       Impact factor: 1.303

5.  Effect of transforming growth factor-beta1 on oestrogen metabolism in MCF-7 and MDA-MB-231 breast cancer cell lines.

Authors:  Y S Ee; L C Lai; K Reimann; P K Lim
Journal:  Oncol Rep       Date:  1999 Jul-Aug       Impact factor: 3.906

6.  Modulation of methylnitrosourea-induced breast cancer in Sprague Dawley rats by dehydroepiandrosterone: dose-dependent inhibition, effects of limited exposure, effects on peroxisomal enzymes, and lack of effects on levels of Ha-Ras mutations.

Authors:  R A Lubet; G B Gordon; R A Prough; X D Lei; M You; Y Wang; C J Grubbs; V E Steele; G J Kelloff; C F Thomas; R D Moon
Journal:  Cancer Res       Date:  1998-03-01       Impact factor: 12.701

7.  Endocrine-immune-paracrine interactions in prostate cells as targeted by phytomedicines.

Authors:  Nora E Gray; Xunxian Liu; Renee Choi; Marc R Blackman; Julia T Arnold
Journal:  Cancer Prev Res (Phila)       Date:  2009-01-13

Review 8.  DHEA and the intracrine formation of androgens and estrogens in peripheral target tissues: its role during aging.

Authors:  F Labrie; A Bélanger; V Luu-The; C Labrie; J Simard; L Cusan; J L Gomez; B Candas
Journal:  Steroids       Date:  1998 May-Jun       Impact factor: 2.668

Review 9.  Multistep tumorigenesis and the microenvironment.

Authors:  Pepper Schedin; Anthony Elias
Journal:  Breast Cancer Res       Date:  2004-02-12       Impact factor: 6.466

View more
  8 in total

1.  Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types.

Authors:  Siddhartha P Kar; Jonathan Beesley; Ali Amin Al Olama; Kyriaki Michailidou; Jonathan Tyrer; ZSofia Kote-Jarai; Kate Lawrenson; Sara Lindstrom; Susan J Ramus; Deborah J Thompson; Adam S Kibel; Agnieszka Dansonka-Mieszkowska; Agnieszka Michael; Aida K Dieffenbach; Aleksandra Gentry-Maharaj; Alice S Whittemore; Alicja Wolk; Alvaro Monteiro; Ana Peixoto; Andrzej Kierzek; Angela Cox; Anja Rudolph; Anna Gonzalez-Neira; Anna H Wu; Annika Lindblom; Anthony Swerdlow; Argyrios Ziogas; Arif B Ekici; Barbara Burwinkel; Beth Y Karlan; Børge G Nordestgaard; Carl Blomqvist; Catherine Phelan; Catriona McLean; Celeste Leigh Pearce; Celine Vachon; Cezary Cybulski; Chavdar Slavov; Christa Stegmaier; Christiane Maier; Christine B Ambrosone; Claus K Høgdall; Craig C Teerlink; Daehee Kang; Daniel C Tessier; Daniel J Schaid; Daniel O Stram; Daniel W Cramer; David E Neal; Diana Eccles; Dieter Flesch-Janys; Digna R Velez Edwards; Dominika Wokozorczyk; Douglas A Levine; Drakoulis Yannoukakos; Elinor J Sawyer; Elisa V Bandera; Elizabeth M Poole; Ellen L Goode; Elza Khusnutdinova; Estrid Høgdall; Fengju Song; Fiona Bruinsma; Florian Heitz; Francesmary Modugno; Freddie C Hamdy; Fredrik Wiklund; Graham G Giles; Håkan Olsson; Hans Wildiers; Hans-Ulrich Ulmer; Hardev Pandha; Harvey A Risch; Hatef Darabi; Helga B Salvesen; Heli Nevanlinna; Henrik Gronberg; Hermann Brenner; Hiltrud Brauch; Hoda Anton-Culver; Honglin Song; Hui-Yi Lim; Iain McNeish; Ian Campbell; Ignace Vergote; Jacek Gronwald; Jan Lubiński; Janet L Stanford; Javier Benítez; Jennifer A Doherty; Jennifer B Permuth; Jenny Chang-Claude; Jenny L Donovan; Joe Dennis; Joellen M Schildkraut; Johanna Schleutker; John L Hopper; Jolanta Kupryjanczyk; Jong Y Park; Jonine Figueroa; Judith A Clements; Julia A Knight; Julian Peto; Julie M Cunningham; Julio Pow-Sang; Jyotsna Batra; Kamila Czene; Karen H Lu; Kathleen Herkommer; Kay-Tee Khaw; Keitaro Matsuo; Kenneth Muir; Kenneth Offitt; Kexin Chen; Kirsten B Moysich; Kristiina Aittomäki; Kunle Odunsi; Lambertus A Kiemeney; Leon F A G Massuger; Liesel M Fitzgerald; Linda S Cook; Lisa Cannon-Albright; Maartje J Hooning; Malcolm C Pike; Manjeet K Bolla; Manuel Luedeke; Manuel R Teixeira; Marc T Goodman; Marjanka K Schmidt; Marjorie Riggan; Markus Aly; Mary Anne Rossing; Matthias W Beckmann; Matthieu Moisse; Maureen Sanderson; Melissa C Southey; Michael Jones; Michael Lush; Michelle A T Hildebrandt; Ming-Feng Hou; Minouk J Schoemaker; Montserrat Garcia-Closas; Natalia Bogdanova; Nazneen Rahman; Nhu D Le; Nick Orr; Nicolas Wentzensen; Nora Pashayan; Paolo Peterlongo; Pascal Guénel; Paul Brennan; Paula Paulo; Penelope M Webb; Per Broberg; Peter A Fasching; Peter Devilee; Qin Wang; Qiuyin Cai; Qiyuan Li; Radka Kaneva; Ralf Butzow; Reidun Kristin Kopperud; Rita K Schmutzler; Robert A Stephenson; Robert J MacInnis; Robert N Hoover; Robert Winqvist; Roberta Ness; Roger L Milne; Ruth C Travis; Sara Benlloch; Sara H Olson; Shannon K McDonnell; Shelley S Tworoger; Sofia Maia; Sonja Berndt; Soo Chin Lee; Soo-Hwang Teo; Stephen N Thibodeau; Stig E Bojesen; Susan M Gapstur; Susanne Krüger Kjær; Tanja Pejovic; Teuvo L J Tammela; Thilo Dörk; Thomas Brüning; Tiina Wahlfors; Tim J Key; Todd L Edwards; Usha Menon; Ute Hamann; Vanio Mitev; Veli-Matti Kosma; Veronica Wendy Setiawan; Vessela Kristensen; Volker Arndt; Walther Vogel; Wei Zheng; Weiva Sieh; William J Blot; Wojciech Kluzniak; Xiao-Ou Shu; Yu-Tang Gao; Fredrick Schumacher; Matthew L Freedman; Andrew Berchuck; Alison M Dunning; Jacques Simard; Christopher A Haiman; Amanda Spurdle; Thomas A Sellers; David J Hunter; Brian E Henderson; Peter Kraft; Stephen J Chanock; Fergus J Couch; Per Hall; Simon A Gayther; Douglas F Easton; Georgia Chenevix-Trench; Rosalind Eeles; Paul D P Pharoah; Diether Lambrechts
Journal:  Cancer Discov       Date:  2016-07-17       Impact factor: 39.397

Review 2.  Androgens and estrogens in benign prostatic hyperplasia: past, present and future.

Authors:  Tristan M Nicholson; William A Ricke
Journal:  Differentiation       Date:  2011-05-26       Impact factor: 3.880

3.  A new antidiabetic compound attenuates inflammation and insulin resistance in Zucker diabetic fatty rats.

Authors:  Min Lu; David Patsouris; Pingping Li; Jaime Flores-Riveros; James M Frincke; Steve Watkins; Simon Schenk; Jerrold M Olefsky
Journal:  Am J Physiol Endocrinol Metab       Date:  2010-02-16       Impact factor: 4.310

4.  Dehydroepiandrosterone suppresses eosinophil infiltration and airway hyperresponsiveness via modulation of chemokines and Th2 cytokines in ovalbumin-sensitized mice.

Authors:  Chian-Jiun Liou; Wen-Chung Huang
Journal:  J Clin Immunol       Date:  2011-06-04       Impact factor: 8.317

5.  Transforming growth factor β1 increase of hydroxysteroid dehydrogenase proteins is partly suppressed by red clover isoflavones in human primary prostate cancer-derived stromal cells.

Authors:  Xunxian Liu; Yun-Shang Piao; Julia T Arnold
Journal:  Carcinogenesis       Date:  2011-09-12       Impact factor: 4.944

6.  Sigma1 Targeting to Suppress Aberrant Androgen Receptor Signaling in Prostate Cancer.

Authors:  Jeffrey D Thomas; Charles G Longen; Halley M Oyer; Nan Chen; Christina M Maher; Joseph M Salvino; Blase Kania; Kelsey N Anderson; William F Ostrander; Karen E Knudsen; Felix J Kim
Journal:  Cancer Res       Date:  2017-02-24       Impact factor: 12.701

7.  TGFβ1 alters androgenic metabolites and hydroxysteroid dehydrogenase enzyme expression in human prostate reactive stromal primary cells: Is steroid metabolism altered by prostate reactive stromal microenvironment?

Authors:  Yun-shang Piao; Paddy Wiesenfeld; Robert Sprando; Julia T Arnold
Journal:  J Steroid Biochem Mol Biol       Date:  2013-06-13       Impact factor: 4.292

Review 8.  A review of age-related dehydroepiandrosterone decline and its association with well-known geriatric syndromes: is treatment beneficial?

Authors:  Nikolaos Samaras; Dimitrios Samaras; Emilia Frangos; Alexandre Forster; Jacques Philippe
Journal:  Rejuvenation Res       Date:  2013-08       Impact factor: 4.663

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.